Fell, Jay B. et al. published their research in Journal of Medicinal Chemistry in 2020 | CAS: 1589082-06-3

(S)-tert-Butyl 3-(cyanomethyl)piperazine-1-carboxylate (cas: 1589082-06-3) belongs to piperazine derivatives. Piperazine is a fairly basic compound and is an amine solvent. Piperazine is formed as a co-product in the ammoniation of 1,2-dichloroethane or ethanolamine. These are the only routes to the chemical used commercially.Synthetic Route of C11H19N3O2

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer was written by Fell, Jay B.;Fischer, John P.;Baer, Brian R.;Blake, James F.;Bouhana, Karyn;Briere, David M.;Brown, Karin D.;Burgess, Laurence E.;Burns, Aaron C.;Burkard, Michael R.;Chiang, Harrah;Chicarelli, Mark J.;Cook, Adam W.;Gaudino, John J.;Hallin, Jill;Hanson, Lauren;Hartley, Dylan P.;Hicken, Erik J.;Hingorani, Gary P.;Hinklin, Ronald J.;Mejia, Macedonio J.;Olson, Peter;Otten, Jennifer N.;Rhodes, Susan P.;Rodriguez, Martha E.;Savechenkov, Pavel;Smith, Darin J.;Sudhakar, Niranjan;Sullivan, Francis X.;Tang, Tony P.;Vigers, Guy P.;Wollenberg, Lance;Christensen, James G.;Marx, Matthew A.. And the article was included in Journal of Medicinal Chemistry in 2020.Synthetic Route of C11H19N3O2 This article mentions the following:

Capping off an era marred by drug development failures and punctuated by waning interest and presumed intractability toward direct targeting of KRAS, new technologies and strategies are aiding in the target’s resurgence. As previously reported, the tetrahydropyridopyrimidines were identified as irreversible covalent inhibitors of KRASG12C that bind in the switch-II pocket of KRAS and make a covalent bond to cysteine 12. Using structure-based drug design in conjunction with a focused in vitro absorption, distribution, metabolism and excretion screening approach, analogs were synthesized to increase the potency and reduce metabolic liabilities of this series. The discovery of the clin. development candidate MRTX849(I)as a potent, selective covalent inhibitor of KRASG12C is described. In the experiment, the researchers used many compounds, for example, (S)-tert-Butyl 3-(cyanomethyl)piperazine-1-carboxylate (cas: 1589082-06-3Synthetic Route of C11H19N3O2).

(S)-tert-Butyl 3-(cyanomethyl)piperazine-1-carboxylate (cas: 1589082-06-3) belongs to piperazine derivatives. Piperazine is a fairly basic compound and is an amine solvent. Piperazine is formed as a co-product in the ammoniation of 1,2-dichloroethane or ethanolamine. These are the only routes to the chemical used commercially.Synthetic Route of C11H19N3O2

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics